HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
Alberto Bretoni, Lucrezia Ferrario, Emanuela FogliaCentre for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, ItalyPurpose: To investigate the implications of the introduction of two hormonal therapies, abiraterone acetate + predniso...
Saved in:
Main Authors: | Bretoni A (Author), Ferrario L (Author), Foglia E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
by: Bretoni A, et al.
Published: (2019) -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015) -
Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
by: Faiza Naseer, et al.
Published: (2021) -
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
by: Channing J Paller, et al.
Published: (2011)